ChipAgents Raises $74M to Scale an Agentic AI Platform to Accelerate Chip Design
17.2.2026 16:00:00 CET | Business Wire | Press Release
ChipAgents, the category leader for Agentic AI platforms in the semiconductor design industry, announced it has closed an oversubscribed $50 million Series A1 funding round, bringing total capital raised to $74 million. The round was led by Matter Venture Partners, a TSMC-backed HardTech VC firm, with participation from existing investors Bessemer Venture Partners, Micron, MediaTek, and Ericsson.
As part of the investment, Wen Hsieh, Founding Managing Partner of Matter VP, will join ChipAgents' Board of Directors, bringing over two decades of expertise and relationships in semiconductor design and manufacturing.
Building the AI Workforce for Chip Design Companies
This new capital will enable ChipAgents to aggressively scale its Agentic AI platform, expand its engineering and research organization, and accelerate global deployment of multi-agent chip teams. ChipAgents is building the foundational AI infrastructure for chip design, with coordinated AI Agents that can plan, reason, execute, and continuously improve across complex silicon programs. By transforming chip development into an AI-native, outcome-driven system, ChipAgents is redefining semiconductor innovations.
“We’re building an Agentic AI workforce for the semiconductor industry,” said William Wang, CEO and Founder of ChipAgents. “Our multi-agent AI teams are not just copilots or AI assistants; they actually take ownership. They read specifications, break down objectives, discuss and implement solutions, validate results, and iterate relentlessly. This is not incremental productivity software. It’s a revolutionary AI execution platform for silicon design.”
“As chip complexity explodes and experienced chip design talent becomes the limiting factor, the future will belong to hybrid human-AI teams with the best AI Agent infrastructure,” Wang added. “ChipAgents enables small IC design teams to operate like much larger organizations that can move at startup speed. This funding accelerates our mission to make AI-driven chip innovations the default model for how all silicon will be designed, built, and shipped.”
Strategic Partnership with Industry Leaders
The investment by Matter Venture Partners, a VC firm with deep roots across the global semiconductor ecosystem, reinforces confidence in ChipAgents’ vision to build the Agentic AI platform powering the next generation of silicon innovation. With leading foundries fabricating the vast majority of the world’s most advanced chips, alignment with investors embedded in this ecosystem positions ChipAgents at the center of a structural shift toward AI-native chip development.
"The semiconductor industry is entering a phase where the limits to chip design productivity are no longer the tools themselves," said Wen Hsieh, Founding Managing Partner of Matter Venture Partners. "The limits are now talent availability, human bandwidth and design iteration speed. ChipAgents addresses this constraint directly with an Agentic AI platform capable of significantly scaling engineering and design capacity alongside advanced manufacturing progress. As the AI ecosystem demands increasingly complex, higher-performing silicon, we believe ChipAgents will be essential for any chip company that wants to shape the future of AI and compute.”
Market Momentum and Customer Traction
Building on the momentum of its Series A that was completed a few months ago, ChipAgents has achieved 140x year-over-year ARR growth and has expanded deployments to 80 leading semiconductor companies, securing several multi-year, multi-million-dollar licensing agreements. The team has scaled from 10 to 46 employees and relocated its headquarters from Santa Barbara to a new state-of-the-art facility in Santa Clara, placing the company at the center of the global semiconductor ecosystem. Across Tier-1 semiconductor programs in live production environments, ChipAgents is delivering step-function performance gains:
- 15x faster specification reading and comprehension
- 240x reduction in formal assertion generation time
- 100% code and functional coverage through formal verification
- 400x faster UVM environment generation
These results translate into significantly compressed verification cycles, full design visibility, and a new level of execution velocity across complex digital IC design programs, enabling teams to ship more silicon with greater speed, confidence and control.
World-Class Advisory Board Expands
Sandeep Bharathi, President of Marvell’s Data Center Group, joined ChipAgents’ Advisory Board, bringing over two decades of experience leading chip development for hyperscale cloud and enterprise infrastructure. His expertise in scaling complex SoC programs from design through high-volume production will help guide ChipAgents through its rapid growth.
“Semiconductor development continues to grow in complexity as systems scale across cloud and enterprise infrastructure. The industry must rethink how engineering teams are supported. ChipAgents is exploring how AI can create design and verification workflows, and I look forward to advising the company as it advances this mission,” said Sandeep Bharathi.
Bharathi joins an advisory board that already includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; John Bowers, Electrical Engineering pioneer, and Erez Tsur, former CEO of Cadence Israel.
About ChipAgents
ChipAgents is an Agentic AI platform that transforms specifications and code into production-ready RTL, verification assets, and automated root-cause analysis, dramatically shortening design and verification cycles. Founded in 2024, the company brings autonomous AI Agents into production semiconductor workflows, serving both design and verification engineers and embedded systems teams at leading semiconductor companies worldwide. The company is headquartered in Santa Clara, California. For more information, visit chipagents.ai
About Matter Venture Partners
Matter Venture Partners is a Silicon Valley-based venture capital firm backing exceptional founders building the most advanced semiconductor, electronics, and Physical AI innovations. With decades of operational expertise and deep strategic relationships, Matter Venture Partners pairs technical insight with long-term conviction to help scale category-defining HardTech startups.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217568914/en/
Contacts
Media Contact:
press@alphadesign.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom